The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
 
Charles A. Leath
Consulting or Advisory Role - GlaxoSmithKline; GOG Foundation; Immunogen; Merck; Natera; Seagen
Research Funding - Abbvie (Inst); Agenus (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Celsion (Inst); Corcept Therapeutics (Inst); Immunogen (Inst); Merck (Inst); Rubius Therapeutics (Inst); Seagen (Inst); Tesaro (Inst)
 
Wei Deng
No Relationships to Disclose
 
Loren K. Mell
Consulting or Advisory Role - Cel-Sci
Research Funding - AstraZeneca; Merck
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Immunogen; Mersana
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Joan L. Walker
Research Funding - Genentech; Pieces Tech (Inst); us biotest
 
Laura L. Holman
No Relationships to Disclose
 
Jayanthi Sivasothy Lea
Consulting or Advisory Role - Roche
 
Sudha R. Amarnath
No Relationships to Disclose
 
Luis Javier Santos-Reyes
Honoraria - Covidien; Merck
Travel, Accommodations, Expenses - Covidien
 
Rebecca Christian Arend
Employment - Signatera (I)
Consulting or Advisory Role - Caris Life Sciences; GlaxoSmithKline; KIYATEC; Leap Therapeutics; Merck; Seagan; Sutro Biopharma; VBL Therapeutics
Research Funding - Champions Oncology; Exelixis; GlaxoSmithKline; Immunogen; Merck
Travel, Accommodations, Expenses - Caris Life Sciences; GlaxoSmithKline; VBL Therapeutics
 
Jyoti Mayadev
Leadership - NRG Oncology
Honoraria - AstraZeneca
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Merck; Primmune Therapeutics; Varian Medical Systems
Travel, Accommodations, Expenses - Merck
 
Naresh Jegadeesh
No Relationships to Disclose
 
Paul Disilvestro
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen Oncology (Inst); Tesaro (Inst)
 
Hye Sook Chon
Honoraria - Curio Science; Envision Communications; Guidepoint Global; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Envision Communications
Travel, Accommodations, Expenses - Agenus
 
Sharad A. Ghamande
Consulting or Advisory Role - Seagen
Speakers' Bureau - Eisai; Tesaro/GSK
Research Funding - Abbvie (Inst); Advaxis (Inst); Akeso Biopharma (Inst); Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Merck Serono (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)
 
Allison M Quick
No Relationships to Disclose
 
Junzo P. Chino
Consulting or Advisory Role - KM Pharmaceutical Consulting; Stryker
 
Helen Mackay
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - Eisai; GlaxoSmithKline; Merck
 
Carol Aghajanian
Consulting or Advisory Role - AstraZeneca/Merck; Eisai; Repare Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)